Rate and Predictors of Interval Esophageal and Gastric Cancers after Esophagogastroduodenoscopy in the United States

Yize R. Wang, Edward Vincent Loftus, Jr, Thomas A. Judge, Steven R. Peikin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Aims: In the United States, little is known about the rates of interval upper gastrointestinal (GI) cancer (possibly missed out) after an esophagogastroduodenoscopy (EGD) is performed. Data from non-US studies reported interval cancer rates of 7-26%. We aimed to study the rate and predictors of interval upper GI cancers in the United States. Methods: Using the random 5% sample of Medicare beneficiaries in the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified patients diagnosed with esophageal or gastric cancer during 2000-2007. EGD performed within 36 months prior to cancer diagnosis was identified using CPT codes. Cancers diagnosed 6-36 months after EGD were defined as interval (vs. detected) cancers. The chi-square test and the multivariate logistic model were used in statistical analysis. Results: Of 751 patients diagnosed with upper GI cancer, 52 patients (6.9%) were diagnosed with interval cancers 6-36 months after EGD. The rate of interval cancers was 5.5% (31/568) for gastroenterologists and 11.5% (21/183) for non-gastroenterologists (p < 0.01). In multivariate logistic regression, EGDs performed by gastroenterologists (vs. non-gastroenterologists: OR 0.46, 95% CI 0.25-0.83) and those in inpatient setting (vs. outpatient: OR 0.53, 95% CI 0.28-0.997) were associated with a lower likelihood of interval cancers. Sensitivity analyses limited to outpatient EGDs or interval cancers 6-30 months after EGDs led to similar results. Conclusions: The rate of interval cancers after EGD is the same as the rate of colonoscopy among Medicare patients in the United States. EGDs performed by gastroenterologists and in in-patient settings were associated with a lesser likelihood of interval cancers.

Original languageEnglish (US)
Pages (from-to)176-180
Number of pages5
JournalDigestion
DOIs
StateAccepted/In press - Nov 22 2016

Fingerprint

Digestive System Endoscopy
Esophageal Neoplasms
Stomach Neoplasms
Neoplasms
Gastrointestinal Neoplasms
Medicare
Outpatients
Logistic Models
Current Procedural Terminology
Colonoscopy
Chi-Square Distribution
Inpatients
Epidemiology
Databases

Keywords

  • Esophageal cancer
  • Esophagogastroduodenoscopy
  • Gastric cancer
  • Interval cancer
  • Outcomes research

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rate and Predictors of Interval Esophageal and Gastric Cancers after Esophagogastroduodenoscopy in the United States. / Wang, Yize R.; Loftus, Jr, Edward Vincent; Judge, Thomas A.; Peikin, Steven R.

In: Digestion, 22.11.2016, p. 176-180.

Research output: Contribution to journalArticle

@article{8c75f7535f52456e8469434331b3fcc9,
title = "Rate and Predictors of Interval Esophageal and Gastric Cancers after Esophagogastroduodenoscopy in the United States",
abstract = "Background and Aims: In the United States, little is known about the rates of interval upper gastrointestinal (GI) cancer (possibly missed out) after an esophagogastroduodenoscopy (EGD) is performed. Data from non-US studies reported interval cancer rates of 7-26{\%}. We aimed to study the rate and predictors of interval upper GI cancers in the United States. Methods: Using the random 5{\%} sample of Medicare beneficiaries in the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified patients diagnosed with esophageal or gastric cancer during 2000-2007. EGD performed within 36 months prior to cancer diagnosis was identified using CPT codes. Cancers diagnosed 6-36 months after EGD were defined as interval (vs. detected) cancers. The chi-square test and the multivariate logistic model were used in statistical analysis. Results: Of 751 patients diagnosed with upper GI cancer, 52 patients (6.9{\%}) were diagnosed with interval cancers 6-36 months after EGD. The rate of interval cancers was 5.5{\%} (31/568) for gastroenterologists and 11.5{\%} (21/183) for non-gastroenterologists (p < 0.01). In multivariate logistic regression, EGDs performed by gastroenterologists (vs. non-gastroenterologists: OR 0.46, 95{\%} CI 0.25-0.83) and those in inpatient setting (vs. outpatient: OR 0.53, 95{\%} CI 0.28-0.997) were associated with a lower likelihood of interval cancers. Sensitivity analyses limited to outpatient EGDs or interval cancers 6-30 months after EGDs led to similar results. Conclusions: The rate of interval cancers after EGD is the same as the rate of colonoscopy among Medicare patients in the United States. EGDs performed by gastroenterologists and in in-patient settings were associated with a lesser likelihood of interval cancers.",
keywords = "Esophageal cancer, Esophagogastroduodenoscopy, Gastric cancer, Interval cancer, Outcomes research",
author = "Wang, {Yize R.} and {Loftus, Jr}, {Edward Vincent} and Judge, {Thomas A.} and Peikin, {Steven R.}",
year = "2016",
month = "11",
day = "22",
doi = "10.1159/000452794",
language = "English (US)",
pages = "176--180",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Rate and Predictors of Interval Esophageal and Gastric Cancers after Esophagogastroduodenoscopy in the United States

AU - Wang, Yize R.

AU - Loftus, Jr, Edward Vincent

AU - Judge, Thomas A.

AU - Peikin, Steven R.

PY - 2016/11/22

Y1 - 2016/11/22

N2 - Background and Aims: In the United States, little is known about the rates of interval upper gastrointestinal (GI) cancer (possibly missed out) after an esophagogastroduodenoscopy (EGD) is performed. Data from non-US studies reported interval cancer rates of 7-26%. We aimed to study the rate and predictors of interval upper GI cancers in the United States. Methods: Using the random 5% sample of Medicare beneficiaries in the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified patients diagnosed with esophageal or gastric cancer during 2000-2007. EGD performed within 36 months prior to cancer diagnosis was identified using CPT codes. Cancers diagnosed 6-36 months after EGD were defined as interval (vs. detected) cancers. The chi-square test and the multivariate logistic model were used in statistical analysis. Results: Of 751 patients diagnosed with upper GI cancer, 52 patients (6.9%) were diagnosed with interval cancers 6-36 months after EGD. The rate of interval cancers was 5.5% (31/568) for gastroenterologists and 11.5% (21/183) for non-gastroenterologists (p < 0.01). In multivariate logistic regression, EGDs performed by gastroenterologists (vs. non-gastroenterologists: OR 0.46, 95% CI 0.25-0.83) and those in inpatient setting (vs. outpatient: OR 0.53, 95% CI 0.28-0.997) were associated with a lower likelihood of interval cancers. Sensitivity analyses limited to outpatient EGDs or interval cancers 6-30 months after EGDs led to similar results. Conclusions: The rate of interval cancers after EGD is the same as the rate of colonoscopy among Medicare patients in the United States. EGDs performed by gastroenterologists and in in-patient settings were associated with a lesser likelihood of interval cancers.

AB - Background and Aims: In the United States, little is known about the rates of interval upper gastrointestinal (GI) cancer (possibly missed out) after an esophagogastroduodenoscopy (EGD) is performed. Data from non-US studies reported interval cancer rates of 7-26%. We aimed to study the rate and predictors of interval upper GI cancers in the United States. Methods: Using the random 5% sample of Medicare beneficiaries in the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified patients diagnosed with esophageal or gastric cancer during 2000-2007. EGD performed within 36 months prior to cancer diagnosis was identified using CPT codes. Cancers diagnosed 6-36 months after EGD were defined as interval (vs. detected) cancers. The chi-square test and the multivariate logistic model were used in statistical analysis. Results: Of 751 patients diagnosed with upper GI cancer, 52 patients (6.9%) were diagnosed with interval cancers 6-36 months after EGD. The rate of interval cancers was 5.5% (31/568) for gastroenterologists and 11.5% (21/183) for non-gastroenterologists (p < 0.01). In multivariate logistic regression, EGDs performed by gastroenterologists (vs. non-gastroenterologists: OR 0.46, 95% CI 0.25-0.83) and those in inpatient setting (vs. outpatient: OR 0.53, 95% CI 0.28-0.997) were associated with a lower likelihood of interval cancers. Sensitivity analyses limited to outpatient EGDs or interval cancers 6-30 months after EGDs led to similar results. Conclusions: The rate of interval cancers after EGD is the same as the rate of colonoscopy among Medicare patients in the United States. EGDs performed by gastroenterologists and in in-patient settings were associated with a lesser likelihood of interval cancers.

KW - Esophageal cancer

KW - Esophagogastroduodenoscopy

KW - Gastric cancer

KW - Interval cancer

KW - Outcomes research

UR - http://www.scopus.com/inward/record.url?scp=84996859611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996859611&partnerID=8YFLogxK

U2 - 10.1159/000452794

DO - 10.1159/000452794

M3 - Article

C2 - 27871069

AN - SCOPUS:84996859611

SP - 176

EP - 180

JO - Digestion

JF - Digestion

SN - 0012-2823

ER -